Naviter Wealth LLC Has $2.38 Million Position in Danaher Co. (NYSE:DHR)

Naviter Wealth LLC raised its stake in Danaher Co. (NYSE:DHR) by 3.2% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 8,535 shares of the conglomerate’s stock after buying an additional 267 shares during the quarter. Naviter Wealth LLC’s holdings in Danaher were worth $2,375,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of the stock. Oak Thistle LLC bought a new position in Danaher during the second quarter worth $363,000. Norden Group LLC acquired a new position in shares of Danaher during the first quarter valued at about $4,151,000. Duality Advisers LP acquired a new position in shares of Danaher during the first quarter valued at about $5,573,000. Investment Research & Advisory Group Inc. acquired a new stake in Danaher during the first quarter worth about $1,186,000. Finally, Diversified Trust Co lifted its position in shares of Danaher by 75.4% in the 2nd quarter. Diversified Trust Co now owns 4,360 shares of the conglomerate’s stock worth $1,090,000 after acquiring an additional 1,874 shares during the period. 79.05% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several equities research analysts have recently weighed in on the stock. The Goldman Sachs Group upped their target price on shares of Danaher from $225.00 to $250.00 and gave the stock a “neutral” rating in a report on Wednesday, July 24th. StockNews.com lowered shares of Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Robert W. Baird boosted their target price on Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a report on Wednesday, July 24th. Wells Fargo & Company began coverage on Danaher in a report on Tuesday, August 27th. They set an “equal weight” rating and a $280.00 price target for the company. Finally, Bank of America boosted their price objective on Danaher from $270.00 to $275.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 24th. Seven investment analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $282.12.

Insider Activity at Danaher

In related news, CFO Matthew Mcgrew sold 16,172 shares of the firm’s stock in a transaction on Thursday, August 1st. The shares were sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the sale, the chief financial officer now directly owns 29,407 shares in the company, valued at $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In related news, CFO Matthew Mcgrew sold 16,172 shares of Danaher stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.84, for a total transaction of $4,525,572.48. Following the completion of the transaction, the chief financial officer now owns 29,407 shares in the company, valued at approximately $8,229,254.88. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $268.37, for a total value of $255,488.24. Following the completion of the sale, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 39,659 shares of company stock worth $11,042,433 in the last quarter. Corporate insiders own 11.10% of the company’s stock.

Danaher Trading Up 2.4 %

NYSE DHR traded up $6.55 on Thursday, reaching $274.58. The company had a trading volume of 451,238 shares, compared to its average volume of 2,707,988. The company has a quick ratio of 1.04, a current ratio of 1.43 and a debt-to-equity ratio of 0.33. Danaher Co. has a 52 week low of $182.09 and a 52 week high of $281.70. The stock has a market cap of $203.38 billion, a price-to-earnings ratio of 45.42, a PEG ratio of 4.49 and a beta of 0.83. The stock’s 50 day moving average is $270.53 and its 200-day moving average is $259.65.

Danaher (NYSE:DHR) last announced its quarterly earnings results on Tuesday, July 23rd. The conglomerate reported $1.72 EPS for the quarter, beating analysts’ consensus estimates of $1.57 by $0.15. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The company had revenue of $5.74 billion during the quarter, compared to analysts’ expectations of $5.59 billion. During the same period in the prior year, the business posted $2.05 EPS. Danaher’s revenue was down 2.9% on a year-over-year basis. Equities analysts predict that Danaher Co. will post 7.59 earnings per share for the current year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 25th. Stockholders of record on Friday, September 27th will be given a dividend of $0.27 per share. The ex-dividend date is Friday, September 27th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.39%. Danaher’s dividend payout ratio is 18.31%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.